1352 completed. 1352 Phase 1, 380 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1352 | Completed 1352 |
| Phase 2 | 380 | Completed 380 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) MK-4700, Pembrolizumab - Malignant Neoplasm | Phase 1 | Completed | Merck Sharp & Dohme LLC | 5 | 2025-04-23 | 2026-03-16 |
| Using Novel Imaging to More Safely Treat Neuroendocrine Tumors Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate - Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor | Phase 1 | Completed | University of Wisconsin, Madison | 4 | 2025-03-07 | 2026-06-23 |
| Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401) 5-Aminolevulinic acid Hydrochloride (Gliolan®), CV01 - Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO) | Phase 1 | Completed | Universität Münster | 16 | 2025-01-27 | 2026-02-27 |
| Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma 123I-ATT001 - Glioma Glioblastoma Multiforme | Phase 1 | Completed | Theragnostics Ltd | 7 | 2024-07-04 | 2026-03-31 |
| Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients FYB206, Keytruda - Melanoma, Stage II, Melanoma Stage III | Phase 1 | Completed | Formycon AG | 96 | 2024-07-01 | 2026-10-20 |
| A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma GME751, Keytruda - EU, Keytruda - US - Melanoma | Phase 1 | Completed | Sandoz | 322 | 2024-05-15 | 2026-07-07 |
| A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors AMG 355, Pembrolizumab - Advanced Solid Tumors | Phase 1 | Completed | Amgen | 77 | 2024-03-07 | 2026-08-11 |
| A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors IMM-6-415 - Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma | Phase 1 / Phase 2 | Completed | Immuneering Corporation | 30 | 2024-02-27 | 2025-05-28 |
| Study of DF6215 in Patients With Advanced Solid Tumors DF6215, pembrolizumab, KEYTRUDA® - Solid Tumor, Adult, Solid Tumor Cancer | Phase 1 | Completed | Dragonfly Therapeutics | 35 | 2023-11-28 | 2026-03-18 |
| A Study of GC101 TIL in Advanced Melanoma (BZ) GC101 TIL - Tumor Infiltrating Lymphocytes, Safety | Phase 1 / Phase 2 | Completed | Shanghai Juncell Therapeutics | 18 | 2023-11-08 | 2025-12-23 |
| Intratumoral PH-762 for Cutaneous Carcinoma PH-762 - Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin | Phase 1 | Completed | Phio Pharmaceuticals Inc. | 22 | 2023-11-07 | 2026-09-21 |
| A Study of Avutometinib for People With Solid Tumor Cancers Avutometinib - Refractory Cancer, CNS Tumors | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2023-10-20 | 2026-11-04 |
| Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg - Glioblastoma | Phase 1 / Phase 2 | Completed | Cantex Pharmaceuticals | 33 | 2023-09-05 | 2026-10-19 |
| Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) ITI-1001 - Glioblastoma | Phase 1 | Completed | Immunomic Therapeutics, Inc. | 10 | 2023-08-21 | 2026-07-01 |
| TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma TN-TC11G, Temozolomide Oral Product, Radiotherapy - Glioblastoma | Phase 1 / Phase 2 | Completed | Grupo Español de Investigación en Neurooncología | 33 | 2023-08-18 | 2026-02-12 |
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors AI-061 - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Completed | OncoC4, Inc. | 18 | 2023-07-11 | 2026-09-14 |
| Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma CV09050101 mRNA vaccine (CVGBM) 12 μg, CV09050101 mRNA vaccine (CVGBM) 25 μg, CV09050101 mRNA vaccine (CVGBM) 50 μg - Glioblastoma | Phase 1 | Completed | CureVac | 37 | 2023-06-01 | 2026-02-18 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. PRRT with 177Lu-DOTATATE - Neuroblastoma | Phase 1 | Completed | Institut Claudius Regaud | 1 | 2023-04-17 | 2026-04-29 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
Showing 20 of 1352. Sign in to see all of them.
Melanoma (579) · Glioblastoma (409) · Glioma (242) · Brain Neoplasms (231) · Astrocytoma (208) · Gliosarcoma (176) · Neoplasms (150) · Central Nervous System Neoplasms (144) · Neuroblastoma (143) · Oligodendroglioma (135) · Carcinoma, Non-Small-Cell Lung (132) · Breast Neoplasms (104) · Carcinoma, Renal Cell (101) · Medulloblastoma (84) · Sarcoma (80)
Neoplasms by Histologic Type (1348) · Neoplasms, Nerve Tissue (1348) · Neoplasms, Germ Cell and Embryonal (1337) · Neoplasms (1202) · Neoplasms by Site (994) · Neoplasms, Glandular and Epithelial (887) · Neoplasms, Neuroepithelial (720) · Neuroendocrine Tumors (637) · Skin and Connective Tissue Diseases (615) · Skin Diseases (613) · Nevi and Melanomas (593) · Skin Neoplasms (565) · Nervous System Diseases (354) · Glioma (329)
Temozolomide (122) · pembrolizumab (75) · Radiotherapy (69) · Nivolumab (57) · Ipilimumab (55) · Cyclophosphamide (54) · Bevacizumab (36) · aldesleukin (36) · Carboplatin (34) · Filgrastim (34) · Radiation (34) · Interleukin-2 (30) · Irinotecan (28) · Cisplatin (24) · Everolimus (21)
National Cancer Institute (NCI) (144) · Memorial Sloan Kettering Cancer Center (35) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (29) · M.D. Anderson Cancer Center (28) · Novartis Pharmaceuticals (25) · Hoffmann-La Roche (22) · Duke University (21) · Dana-Farber Cancer Institute (19) · St. Jude Children's Research Hospital (18) · Children's Oncology Group (17) · H. Lee Moffitt Cancer Center and Research Institute (17) · Merck Sharp & Dohme LLC (16) · New Approaches to Neuroblastoma Therapy Consortium (15) · Jonsson Comprehensive Cancer Center (14) · Fred Hutchinson Cancer Center (12)
United States (1070) · France (92) · Canada (88) · Spain (87) · Australia (82) · Germany (81) · United Kingdom (62) · Italy (52) · Netherlands (51) · Switzerland (43) · Belgium (38) · China (32) · Japan (23) · South Korea (23) · Denmark (20)
Darell D. Bigner, MD, PhD (6) · F. Stephen Hodi, MD (6) · Steven A. Rosenberg, MD, PhD (6) · Craig L. Slingluff, MD (5) · David A. Reardon, MD (5) · Henry S. Friedman, MD (5) · Michael Prados, MD (5)
PMID 31401903, PMID 32747469, PMID 22256804, PMID 23377664, PMID 23545055, PMID 23676418, PMID 24577748, PMID 24983357, PMID 25837513, PMID 32078016, PMID 32350119, PMID 34311780, PMID 36648215, PMID 39504507, PMID 41920422, PMID 10394416, PMID 10797354, PMID 10811235, PMID 10890744, PMID 11410496, PMID 11595689, PMID 11874634, PMID 12039921, PMID 12573762, PMID 12576434, PMID 12721262, PMID 12749708, PMID 12749710, PMID 12833467, PMID 12947072, PMID 14577912, PMID 14670747, PMID 14767498, PMID 14769136, PMID 14769140, PMID 15033677, PMID 15292713, PMID 15667958, PMID 15696196, PMID 15758009, PMID 15814645, PMID 15937544, PMID 15944250, PMID 16012795, PMID 16061868, PMID 16170172, PMID 16192602, PMID 16234526, PMID 16283570, PMID 16421427
2016 (15), U01CA081457 (13), 2019 (12), 2023 (12), P01CA081403 (12), U01CA097452 (10), UM1CA097452 (10), P30CA008748 (9), U01CA062475 (9), 2014 (8), 2018 (8), 2009 (7), 2017 (7), U10CA025224 (7), P30CA015083 (6)